% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{DeTemple:302794,
      author       = {V. K. DeTemple and M. Kaatz and E. Stockfleth and C. Scheel
                      and Y. Angela and R. Gutzmer and U. Leiter and F. Meier and
                      D. Schadendorf$^*$ and E. Livingstone and C. Gebhardt and I.
                      von Wasielewski and M. Weichenthal and P. Mohr and J. Hassel
                      and C. Pföhler and J. C. Simon and F. Jochims and P.
                      Terheyden and J. Ulrich and S. Haferkamp and K. Drexler and
                      B. Schilling and V. Glutsch and L. Heinzerling and C.
                      Berking and S. Ugurel and D. Tomsitz},
      title        = {{R}eal-world experience with first- versus second-line
                      cemiplimab for advanced basal cell carcinoma.},
      journal      = {European journal of cancer},
      volume       = {225},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01334},
      pages        = {115590},
      year         = {2025},
      abstract     = {The anti-PD1 antibody (PD1i) cemiplimab is approved as
                      second-line treatment for locally advanced or metastatic
                      basal cell carcinoma (BCC), resulting in an ORR of 20-30
                      $\%.$ This study aimed to investigate the efficacy of
                      cemiplimab as first-line or second-line treatment of BCC in
                      a German real-world patient cohort.Patients with
                      histologically confirmed locally advanced or metastatic BCC
                      who were treated with cemiplimab were retrospectively
                      identified from the prospective multicenter real-world skin
                      cancer registry ADOREG. Study endpoints were overall
                      response rate (ORR), progression-free survival (PFS), and
                      overall survival (OS). Therapy outcome was compared between
                      patients receiving first-line cemiplimab and patients
                      treated with cemiplimab in second-line.37 patients from 17
                      skin cancer centers were identified who received cemiplimab.
                      The median follow-up after start of any first-line treatment
                      was 37.1 months, and 17.9 months after initiation of any
                      cemiplimab treatment. Patients who received first-line
                      cemiplimab (n = 8) had an ORR of 62.5 $\%,$ compared to an
                      ORR of 31.0 $\%$ for patients who received second-line
                      cemiplimab (n = 29); Median PFS was 19.8 months for
                      first-line cemiplimab and 5.3 months for second-line
                      cemiplimab. Reinduction with HHIs after progression on
                      second-line cemiplimab resulted in an ORR of 20.0 $\%$ and a
                      median PFS of 3.8 months.We demonstrate a comparable outcome
                      for cemiplimab as second-line treatment of BCC in our
                      real-world patient cohort as reported in previous
                      registration studies. Additionally, we found a trend for a
                      more favorable outcome in first-line therapy, suggesting a
                      rationale to further investigate cemiplimab as first-line
                      treatment of advanced BCC.},
      keywords     = {Basal cell carcinoma (Other) / Cemiplimab (Other) /
                      Hedgehog inhibitor (Other) / Immune checkpoint inhibitor
                      (Other) / Real world data (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40580809},
      doi          = {10.1016/j.ejca.2025.115590},
      url          = {https://inrepo02.dkfz.de/record/302794},
}